Findings

What do systematic reviews say?

387 questions · 404 findings · 22 reviews · Gut

No studies found 96 · 23.8%GRADE not reported 3 · 0.7%Very low 108 · 26.7%Low 96 · 23.8%Moderate 69 · 17.1%High 32 · 7.9%

Overall survival (surviving rates) · patients with resectable disease

The intervention showed no clear difference in overall survival (surviving rates) (low certainty).

1 finding from 1 review

Extent of lymph node dissection for adenocarcinoma of the stomach 2015 · Cochrane Headline outcomes only
HR 0.91 [0.71, 1.17]
5 studies · 1653 participants
Low

Disease specific survival (surviving rates) · patients with resectable disease

The intervention probably leads to lower disease specific survival (surviving rates) (moderate certainty).

1 finding from 1 review

Extent of lymph node dissection for adenocarcinoma of the stomach 2015 · Cochrane Headline outcomes only
HR 0.81 [0.71, 0.92]
4 studies · 1599 participants
Moderate

Disease free survival (surviving rates) · patients with resectable disease

The intervention showed no clear difference in disease free survival (surviving rates) (moderate certainty).

1 finding from 1 review

Extent of lymph node dissection for adenocarcinoma of the stomach 2015 · Cochrane Headline outcomes only
HR 0.95 [0.84, 1.07]
3 studies · 1332 participants
Moderate

Postoperative mortality (within 30 days from surgery) · patients with resectable disease

The intervention leads to higher postoperative mortality (within 30 days from surgery) (high certainty).

1 finding from 1 review

Extent of lymph node dissection for adenocarcinoma of the stomach 2015 · Cochrane Headline outcomes only
RR 2.02 [1.34, 3.04]
5 studies · 1653 participants
High

Symptomatic remission · Patients with quiescent ulcerative colitis

Rectal 5‐ASA may leads to higher symptomatic remission compared with placebo (low certainty).

1 finding from 1 review

Rectal 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis 2012 · Cochrane Headline outcomes only
RR 2.22 [1.26, 3.9]
4 studies · 301 participants
Low

Symptomatic remission · Patients with quiescent ulcerative colitis

Rectal 5‐ASA showed no clear difference in symptomatic remission compared with oral 5‐ASA (low certainty).

1 finding from 1 review

Rectal 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis 2012 · Cochrane Headline outcomes only
RR 1.24 [0.92, 1.66]
2 studies · 69 participants
Low

Endoscopic remission · Patients with quiescent ulcerative colitis

Rectal 5‐ASA showed no clear difference in endoscopic remission compared with oral 5‐ASA (low certainty).

1 finding from 1 review

Rectal 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis 2012 · Cochrane Headline outcomes only
RR 1.14 [0.9, 1.45]
2 studies · 91 participants
Low